On September 16, Jiang Wei, member of the party group and deputy director of the Provincial Bureau, led the relevant personnel of the Administrative Examination and Approval Department and the Pharmaceutical and Equipment Business Supervision Department to investigate the Taizhou drug production and operation enterprises, listen face-to-face to the opinions and suggestions on the management of drug production and business licenses under the new system, understand the development requirements of enterprises, and establish communication channels.
Jiang Wei and his party first learned about the basic situation of drug warehousing and logistics of Jiangsu Huawei Pharmaceutical Logistics Co., Ltd. in Taizhou Pharmaceutical Park, the status of drug third-party logistics activities, listened in detail to the introduction of the basic situation of the enterprise's drug warehousing and logistics and the operation of the drug third-party logistics platform, and the Taizhou Inspection Sub-bureau and Taizhou Pharmaceutical Park's risk control of drug quality and safety in the enterprise's operation mode. Jiang Wei pointed out that the provincial bureau should adopt an inclusive and prudent attitude, strengthen guidance to enterprises, and urge enterprises to strengthen the management of enterprises settled on the platform to ensure the compliance of operations and the quality and safety of drugs.
In Jiangsu Ruike Biotechnology Co., Ltd., we focused on the supporting facilities such as the production workshop of the recombinant two-component new crown pneumonia vaccine (CHO cells) to understand the industrialization process of the new crown vaccine. Jiang Wei hopes that enterprises will complete clinical research on vaccines as soon as possible, achieve product launch as soon as possible, and contribute to the new stage of fighting the new crown pneumonia epidemic.
Through in-depth production workshop of Yangtze River Pharmaceutical Group Jiangsu Co., Ltd., on-site inspection of the production process of traditional Chinese medicine tablets, listen to the special report of the enterprise's traditional Chinese medicine formula granule project, and carry out discussions and exchanges on improving the quality control management of the production of traditional Chinese medicine formula granules. Jiang Wei pointed out that the pilot of traditional Chinese medicine formula granules has ended, and enterprises should accelerate standard research, increase investment in research and development, strengthen quality management, and play a demonstration role in making the province's traditional Chinese medicine formula granule industry bigger and stronger.
Taizhou Inspection Branch of the Provincial Bureau, Taizhou Municipal Market Supervision and Administration Bureau, and Taizhou Pharmaceutical Park participated in the survey.
【Source: Jiangsu Provincial Drug Administration_Provincial Bureau Information】
Disclaimer: The copyright of this article belongs to the original author, if there is an error in the source or infringement of your legitimate rights and interests, you can contact us through the mailbox, we will deal with it in a timely manner. Email address: [email protected]